Fulgent Genetics(US:FLGT) Globenewswire·2026-03-20 00:00Core Viewpoint - Fulgent Genetics Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price after issuing lower-than-expected guidance for 2026 [3][4]. Group 1: Company Performance - On February 27, 2026, Fulgent reported its fourth quarter and full year 2025 financial results, which included guidance for 2026 that was lower than market expectations [3]. - The decline in guidance was attributed to the company's largest customer moving a significant volume of its work in-house [3]. - Following the announcement, Fulgent's share price fell by $9.43, or approximately 38.1%, from $24.76 on February 26, 2026, to $15.33 on February 27, 2026 [3]. Group 2: Legal Investigation - Kirby McInerney LLP is conducting an investigation on behalf of Fulgent investors regarding possible violations of federal securities laws or other unlawful business practices by the company or its senior management [1][4]. - As of now, no lawsuit has been filed, and the investigation is ongoing to determine if claims can be brought under federal securities laws [4].